The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 14.72%.However, over the last six months, we can see a weaker performance of 48.04%. Over the last 30 days, the price of MREO has leaped by -12.83%. And in the last five days, it has fallen by -3.28%.
Mereo Biopharma Group Plc ADR experienced a rather steady stock market performance. The highest value in the past year was recorded at $4.36 on 02/05/24 and the lowest value was $0.92 on 05/31/23.
52-week price history of MREO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Mereo Biopharma Group Plc ADR’s current trading price is -39.22% away from its 52-week high, while its distance from the 52-week low is 188.01%. The stock’s price range during this period has varied between$0.92 and $4.36. The Mereo Biopharma Group Plc ADR’s shares, which operate in the Healthcare, saw a trading volume of around 0.81 million for the day, a figure considerably lower than their average daily volume of 1.65 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Mereo Biopharma Group Plc ADR (MREO) has experienced a quarterly decline of -10.77% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 371.16M and boasts a workforce of 33 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.01, with a change in price of +0.57. Similarly, Mereo Biopharma Group Plc ADR recorded 1,419,651 in trading volume during the last 100 days, posting a change of +27.10%.
MREO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MREO stands at 0.16. Similarly, the long-term debt-to-equity ratio is also 0.08.
MREO Stock Stochastic Average
Mereo Biopharma Group Plc ADR’s raw stochastic average for the past 50 days is presently 7.60%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 13.09%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 10.08% and 9.29%, respectively.
